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Abstract
Background Dupilumab has demonstrated efficacy and acceptable safety in adults and children (aged 6–17 years)
with moderate-to-severe atopic dermatitis (AD), but effective systemic therapy with a favorable risk–benefit profile in
younger children remains a significant unmet need.
Objectives To determine the pharmacokinetics, safety and efficacy of single-dose dupilumab in children with severe
AD aged ≥6 months to <6 years.
Methods This open-label, multicenter, phase 2, sequential, two-age cohort, two-dose level study (LIBERTY AD PRE-
SCHOOL; NCT03346434) included an initial cohort of older children aged ≥2 to <6 years, followed by a younger cohort
aged ≥6 months to <2 years. Pharmacokinetic sampling, safety monitoring and efficacy assessments were performed
during the 4-week period after a single subcutaneous injection of dupilumab, in two sequential dosing groups (3 mg/kg,
then 6 mg/kg). The use of standardized, low-to-medium potency topical corticosteroids was allowed.
Results Forty patients were enrolled (20/age cohort, 10/dose level within a cohort) between December 20, 2017 and
July 22, 2019. Within each age cohort, pharmacokinetic exposures after a single injection of dupilumab increased in a
greater than dose-proportional manner. At week 3, treatment with 3 and 6 mg/kg dupilumab reduced scores of mean
Eczema Area and Severity Index by 44.6% and 49.7% (older cohort) and 42.7% and 38.8% (younger cohort), and
mean Peak Pruritus NRS scores by 22.9% and 44.7% (older cohort) and 11.1% and 18.2% (younger cohort),
respectively. At week 4, improvements in most efficacy outcomes diminished in both age groups, particularly with the
lower dose. The safety profile was comparable to that seen in adults, adolescents and children.
Conclusions Single-dose dupilumab was generally well tolerated and substantially reduced clinical signs/symptoms
of AD. Slightly better responses were seen in older than younger children. The pharmacokinetics of dupilumab were
non-linear, consistent with previous studies in adults and adolescents.
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Introduction
Atopic dermatitis (AD) is one of the most common skin disor-
ders in infants and children,1 with onset under the age of
6 months in 45%, under the age of 1 year in 60% and within the
first 5 years in 89% of all cases.2 The prevalence has been esti-
mated at 15–38% in children aged <5 years in the USA3 and
21.5% in children aged <2 years in Germany.4
Atopic dermatitis markedly affects the quality of life (QoL) of
both children and their families. In one study, nearly two-thirds
of children with severe AD had moderately-to-highly impaired
QoL.5 In infants, the greatest impact of AD includes itching,
sleep loss, mood and behavioral changes.6,7 In children, AD dis-
turbs sleep, increases economic costs, parental fatigue and irri-
tability, impairs daily activities and reduces leisure and family
time as well as psychological and emotional well-being.5,8,9
The so-called ‘atopic march’ in a subset of younger children,
referring to the increased risk of developing asthma and/or aller-
gic rhinitis in children with a history of AD and food allergies,
suggests that AD may be an ‘entry point’ for subsequent allergic
disease.10 An estimated 60% of infants and young children with
severe AD and 30% with mild AD develop asthma.11 Despite the
immune dysregulation shared by all atopic diseases, standard-of-
care treatments have focused on long-term use of distinct topical
products for skin, inhaled medications for asthma, nasal sprays
for rhinitis and oral antihistamines for itch. Management of
these related conditions is often disjointed. Thus, there is a high
need for a therapy that concurrently treats comorbid diseases in
an effective manner.
In children with AD, there is a significant unmet need for a
therapy with a favorable risk–benefit profile that can lead to
rapid disease improvement. Pharmacologic management of AD
in children is primarily limited to topical corticosteroids (TCS).
Younger children using TCS are at highest risk of systemic
absorption, with potential growth retardation and hypothala-
mic–pituitary axis suppression, due to their developmental sta-
tus and higher ratio of body surface area (BSA) to weight.12 TCS
also cause epidermal atrophy, thereby exacerbating the already
defective skin barrier in AD. Clinically relevant thinning of the
epidermis occurs after 2 weeks of a potent steroid on the fore-
arm of an adult with AD.13 Non-corticosteroid alternatives, such
as the topical calcineurin inhibitors (TCI) tacrolimus and pime-
crolimus, are used to minimize chronic TCS exposure in AD,
but access to these medications is often limited by payers, based
on labeling for children aged >2 years.14–16 The use of systemic
corticosteroids is strongly discouraged in AD,17while other sys-
temic immunosuppressants such as cyclosporine, methotrexate,
azathioprine, and mycophenolate mofetil have been used off-la-
bel, despite significant potential side effects, including procar-
cinogenic, hepatic and renal toxicity.18–22 Immunomodulating
treatment may impact immune development in children, and
the immune mechanisms underlying AD in pediatric patients
may differ from those in adults;23,24 therefore, safety and efficacy
of immunomodulatory agents should be assessed in dedicated,
age-specific clinical trials.
Dupilumab, a fully human VelocImmune-derived mono-
clonal antibody,25,26 inhibits signaling of interleukin-4 and inter-
leukin-13. Dupilumab clinical trial data have shown that
interleukin-4 and interleukin-13 are key drivers of type 2 inflam-
mation that play a major role in AD, asthma, chronic rhinosi-
nusitis with nasal polyps (CRSwNP) and eosinophilic
esophagitis.27 In multiple phase 3 trials, dupilumab proved safe
and effective for treating moderate-to-severe AD in patients aged
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>12 years and severe AD in patients as young as 6 years.28–34
Dupilumab is also approved for the treatment of asthma and
CRSwNP, other atopic diseases.35–40
In this article, we describe a phase 2 open-label study to deter-
mine the pharmacokinetics (PK), safety and efficacy of single-




R668-AD-1539 (ClinicalTrials.gov Identifier: NCT03346434) is a
phase 2/3, two-part study. Reported here is the first part (LIB-
ERTY AD PRE-SCHOOL), an open-label, single, ascending-
dose, sequential cohort, multicenter, global, phase 2 study inves-
tigating the PK, safety and efficacy of subcutaneous dupilumab
(Fig. 1). Older patients (aged ≥2 to <6 years) were enrolled first,
followed by the younger cohort (aged ≥6 months to <2 years).
A subgroup of 10 patients in each cohort was treated with the
lower weight-based dose (3 mg/kg) followed by another sub-
group treated with the higher dose (6 mg/kg). To ensure ade-
quate distribution of patients within each age cohort, the
maximum number of patients enrolled at a given dose level was
restricted to seven patients in each of the subgroups: 2 to
<4 years and 4 to <6 years in the older cohort, and 6 months to
<1 year and 1 to <2 years in the younger cohort.
The study consisted of a screening period (day 35 to day
1), baseline visit (day 1) and single-dose treatment on day 1,
followed by a 4-week PK sampling period. Patients were then
offered the opportunity to enrol in an open-label extension
(OLE) study R668-AD-1434 (LIBERTY AD PED-OLE,
NCT02612454). Those who declined or were ineligible to parti-
cipate in the OLE were followed for an additional 4 weeks.
The study was conducted in accordance with the provisions
of the Declaration of Helsinki, the International Conference on
Harmonization Good Clinical Practices guideline and applicable
regulatory requirements. The protocol was reviewed and
approved by institutional review boards/ethics committees at all
sites. For all patients, written informed consent was obtained
from a parent or legal guardian.
Patients and treatment
The main inclusion criteria were as follows: male or female aged
≥6 months to <6 years at the screening visit; diagnosis of AD
according to the American Academy of Dermatology consensus
criteria at the screening visit;41 documented recent history
(within 6 months before the screening visit) of inadequate
response to topical AD medication(s); Investigator’s Global
Assessment (IGA) score of 4, Eczema Area and Severity Index
(EASI) score ≥21 and affected BSA ≥15%.
The 6 mg/kg dose was anticipated to provide drug exposure
comparable to a single dose of dupilumab 300 mg in adult
patients.42,43 The 3 mg/kg dose was evaluated first within each
age group, to allow safety evaluation before progressing to the
6 mg/kg dose. The results from this phase 2 study were planned
to inform dose selection for the pivotal, randomized, double-
blinded, parallel-group, placebo-controlled, phase 3 study (LIB-
ERTY AD INFANT) to evaluate the efficacy, safety and
immunogenicity of multiple doses of dupilumab administered
concomitantly with TCS over 16 weeks.
Standardized, low-to-medium potency TCS with or without
TCI were allowed; high-potency TCS, systemic non-steroidal
immunosuppressants and systemic corticosteroids could be used
only as rescue treatment. Other inclusion/exclusion criteria and
prohibited medications/treatments are summarized in the
Appendix S1 (Supporting Information).
Outcomes assessed
Primary endpoints were as follows: the concentration of func-






SC dupilumab 3 mg/kg single
dose (4 or 8 weeks of follow-up)
SC dupilumab 3 mg/kg single
dose (4 or 8 weeks of follow-up)
SC dupilumab 6 mg/kg single
dose (4 or 8 weeks of follow-up)
SC dupilumab 6 mg/kg single





Figure 1 Study design. Note: Patients who continued into the open-label extension studies were to undergo a 4-week safety follow-up,
while patients who did not continue were to undergo an 8-week safety follow-up. SC, subcutaneous.
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(summary statistics of drug concentration and PK parameters);
incidence and severity of treatment-emergent adverse events
(TEAEs) throughout the study. Secondary endpoints were as fol-
lows: incidence of serious adverse events (SAE) and severe
TEAEs up to week 4; percentage change in EASI (scale of 0–72);
SCORing Atopic Dermatitis (SCORAD) score (scale 0–103)
from baseline to week 4; and proportion of patients with an IGA
score of 0 or 1 (on a 5-point scale) at week 4. Other endpoints
were as follows: proportions of patients with ≥75% improve-
ment from baseline in EASI (EASI-75) or ≥50% improvement
from baseline in EASI (EASI-50) at week 4; percentage change in
caregiver-reported Peak Pruritus numerical rating scale (NRS;
scale 0–10) from baseline to week 4; and change in BSA affected
from baseline to week 4. Per-protocol, the study visit for week 3
was defined as day 18  3 days, and week 4 as day 29  3 days.
Pharmacokinetic analysis
Functional dupilumab concentrations in serum were analyzed
using a validated enzyme-linked immunosorbent assay (ELISA)
as previously described.44 The lower limit of quantitation
(LLoQ) for dupilumab in undiluted human serum is 0.0780 mg/L.
Serum for PK analyses was collected at baseline (before dupilu-
mab injection) and on study days 3, 8, 18 and 29.
Pharmacokinetics parameters, including maximum concen-
tration (Cmax), dose-normalized Cmax (Cmax/dose), time to max-
imum concentration (tmax), last observed concentration (Clast),
time to last observed concentration (tlast), area under the curve
(AUC) from time zero to the last observed concentration
(AUClast) and dose-normalized AUClast (AUClast/dose), were
determined using non-compartmental methods and actual sam-
pling times. Mean concentration–time profiles are presented
using nominal sampling times.
Biomarker analysis
Prespecified analyses of blood eosinophil count, serum thymus
and activation-regulated chemokine (TARC/CCL17) and serum
total IgE were conducted on samples collected at baseline and
various times during treatment. Additional details on the
methodology are in the Appendix S1 (Supporting Information).
Statistical analysis
Because the primary objective was to evaluate safety and PK, no
formal power calculations based on efficacy endpoints were per-
formed. A total of 10 patients in each dose group was considered
adequate to characterize the safety and PK profiles.
Descriptive statistics of functional dupilumab serum concen-
tration at each time point by dose are reported from the PK
analysis set (all treated patients who received any study drug and
who had ≥1 non-missing functional dupilumab measurement
postdose).
Safety and efficacy were assessed in the safety analysis set con-
sisting of all treated patients who received ≥1 dose of dupilumab.
Efficacy analyses were performed using an observed method,
without censoring. Because of the small cohorts, we report no
inferential statistical analyses; all efficacy outcomes are summa-
rized by descriptive statistics. All analyses were performed using
SAS version 9.4 (Cary, NC, USA) or higher.
Results
Patients
Between December 20, 2017 and July 22, 2019, 40 patients (20
aged ≥2 to <6 years and 20 aged ≥6 months to <2 years; 10 at
each dose level within an age cohort) were screened and
enrolled. Patient screening was done in 21 of 30 sites initiated in
the USA, UK and Germany. All patients in the older cohort
completed the study and transitioned to the OLE study; in the
younger cohort, one patient withdrew consent and was discon-
tinued from study prematurely during the safety follow-up per-
iod, and two patients completed the study but did not continue
into the OLE. All patients were included in the safety analysis
set.
Of all study patients, 10 were ≥4 to <6 years old, 10 were ≥2
to <4 years old, 14 were ≥1 to <2 years old, and six were
≥6 months to <1 year old. Baseline demographics and charac-
teristics were, in general, comparable between the treatment
groups within each age cohort. Overall, disease characteristics
were consistent with severe AD (Table 1). In the older cohort,
40% had used systemic AD medications including 25% who had
used oral corticosteroids and 20% non-steroidal immunosup-
pressants. All patients had ≥1 concurrent atopic/allergic comor-
bidity at baseline; more than half had food allergy or allergic
rhinitis. In the younger cohort, 40% of patients had previously
used systemic medications for AD, including 35% who had used
oral corticosteroids and 5% non-steroidal immunosuppressants
(Table 1). Most patients had ≥1 concurrent atopic/allergic
comorbidity at baseline, of which more than half had a food
allergy (Table 1).
Dupilumab pharmacokinetics
Within each age cohort, the higher 6 mg/kg dupilumab dose led
to higher concentrations in serum that persisted for longer peri-
ods of time than the lower 3 mg/kg dose. Maximum concentra-
tions of dupilumab in serum were similar between age cohorts at
each dose level and were observed 2 days after injection in most
patients (Fig. 2). Mean Cmax in the 3 and 6 mg/kg dose groups
of the older cohort were 25.2 and 49.8 mg/L, respectively, and in
the younger cohort 20.1 and 46.1 mg/L, respectively (Table S1,
Supporting Information). Total exposure of dupilumab
increased in a greater than dose-proportional manner between
dose levels within each age cohort and was slightly higher in the
older cohort at each dose level. Mean AUClast increased from
198 day∙mg/L for the 3 mg/kg dose to 622 day∙mg/L for the
6 mg/kg dose in the older cohort, and from 123 day∙mg/L for
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the 3 mg/kg dose to 493 day∙mg/L for the 6 mg/kg dose in the
younger cohort (Table S1, Fig. S1, Supporting Information).
Mean concentrations of dupilumab in serum were below the
LLoQ by week 4 in the 3 mg/kg dose groups, but remained mea-
surable in the 6 mg/kg groups.
Efficacy
In the older cohort, both dupilumab doses led to improvements
in clinical AD signs and symptoms at week 3, as assessed by
reductions from baseline in mean EASI, total SCORAD,
SCORAD visual analog scale (VAS) itch scores (Table 2, Fig. 3a,
b) and extent of BSA involvement. SCORAD VAS sleep scores
also improved at week 3, but only with the 6 mg/kg dose; the
apparent lack of response with the 3 mg/kg dose was driven by
one patient with outlier values (Table 2). EASI scores decreased
by 44.6% with the 3 mg/kg and 49.7% with the 6 mg/kg dose
(Table 2). Improvement in AD signs was also shown by the pro-
portions of patients with EASI-50 (50% and 50%) and EASI-75
(30% and 20%) at week 3 after the single dose of 3 and 6 mg/
kg, respectively (Table 2, Fig. 3c,d). Itch was also improved, as
shown by mean reductions in caregiver-reported Peak Pruritus
NRS of 22.9% and 44.7% from baseline at week 3 for the 3 and
6 mg/kg doses, respectively (Table 2, Fig. 3e).
Atopic dermatitis clinical signs improved in both dose groups
of the younger cohort. EASI scores decreased by a mean 42.7%
and 38.8% at week 3 with the 3 and 6 mg/kg doses, respectively
Table 1 Baseline demographics and clinical characteristics













Age, mean (SD), months 45.8 (16.13) 53.2 (11.23) 15.4 (6.96) 15.9 (5.51)
Age category, n (%), months
≥48 to <72 4 (40.0) 6 (60.0) N/A N/A
≥24 to <48 6 (60.0) 4 (40.0) N/A N/A
≥12 to <24 N/A N/A 7 (70.0) 3 (30.0)
≥6 to <12 N/A N/A 3 (30.0) 7 (70.0)
Male, n (%) 6 (60.0) 7 (70.0) 9 (90.0) 8 (80.0)
Race, n (%)
White 7 (70.0) 8 (80.0) 6 (60.0) 7 (70.0)
Black or African American 3 (30.0) 1 (10.0) 1 (10.0) 2 (20.0)
Asian 0 1 (10.0) 2 (20.0) 1 (10.0)
Weight, mean (SD), kg 16.57 (3.83) 17.61 (3.59) 9.66 (1.67) 9.89 (1.96)
BMI, mean (SD), kg/m2 16.15 (1.93) 16.29 (1.72) 17.11 (1.81) 17.53 (2.59)
Duration of AD, mean (SD), months 40.9 (14.32) 50.6 (10.73) 13.7 (6.55) 13.4 (5.44)
EASI, mean (SD), scale 0–72 35.2 (9.21) 40.2 (11.81) 34.4 (14.25) 36.1 (12.94)
Caregiver-reported Peak Pruritus NRS, mean (SD), scale 0–10 8.4 (1.24) 8.1 (1.45) 7.6 (2.55) 8.5 (0.71)
BSA involvement, mean (SD), % 58.1 (11.09) 67.5 (16.05) 55.3 (25.66) 57.9 (21.37)
SCORAD score, mean (SD), range 0–103 73.5 (10.20) 75.1 (8.08) 69.8 (13.10) 75.9 (11.74)
Prior systemic medication use for AD, n (%) 5 (50.0) 3 (30.0) 3 (30.0) 5 (50.0)
Oral corticosteroids 4 (40.0) 1 (10.0) 2 (20.0) 5 (50.0)
Non-steroidal immunosuppressants 1 (10.0) 3 (30.0) 1 (10.0) 0
Cyclosporine 1 (10.0) 1 (10.0) 0 0
Methotrexate 0 2 (20.0) 1 (10.0) 0
Proportions of patients with ≥1 current history of
atopic/allergic diseases other than AD,† n (%)
10 (100.0) 10 (100.0) 6 (60.0) 8 (80.0)
Food allergy 10 (100.0) 8 (80.0) 5 (50.0) 7 (70.0)
Allergic rhinitis 7 (70.0) 6 (60.0) 3 (30.0) 3 (30.0)
Other allergies 6 (60.0) 4 (40.0) 1 (10.0) 5 (50.0)
Asthma 3 (30.0) 3 (30.0) 0 0
Hives 3 (30.0) 2 (20.0) 1 (10.0) 1 (10.0)
Allergic conjunctivitis (keratoconjunctivitis) 0 2 (20.0) 0 0
AD, atopic dermatitis; BMI, body mass index; BSA, body surface area; EASI, Eczema Area and Severity Index; N/A, not applicable; NRS, numerical rating
scale; SCORAD, SCORing Atopic Dermatitis; SD, standard deviation.
†Comorbidities were documented based on history provided by the caregiver.
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(Table 2, Fig. 3a). Total SCORAD scores, as well as SCORAD
VAS scores for sleep and itch, and percentage of BSA affected
also reduced with both dupilumab doses at week 3 (Table 2 and
Fig. 3b). The proportion of patients with EASI-50 was 50% and
40%, and with EASI-75 was 20% and 0% at week 3 after the 3
and 6 mg/kg doses, respectively, while caregiver-reported Peak
Pruritus NRS scores decreased by a mean of 11.1% and 18.2%
(Table 2, Fig. 3c–e).
At week 4, the reduction in efficacy outcomes, such as EASI,
SCORAD and caregiver-reported Peak Pruritus NRS scores,
started to reverse, but was better sustained in the higher dose
groups in both age groups. All efficacy outcomes were overall
improved compared with baseline (Table 2; Fig. S2, Supporting
Information) and, in general, were numerically higher in the
6 mg/kg cohorts (Table 2).
Safety
In the older cohort, five TEAEs were reported in the 3 mg/kg
group and three TEAEs in the 6 mg/kg group. The incidence of
TEAEs was similar across treatment groups (Table 3), and the
severity of all TEAEs was mild or moderate. One SAE (anaphy-
lactic reaction) was reported with dupilumab 3 mg/kg in a
patient with a history of anaphylaxis to peanuts and documented
egg, peanut, dairy and soya food allergies, immediately after a
meal suspected to contain nuts. This SAE was not considered
treatment-related based on the history of food allergies and ana-
phylaxis, as well as the temporal onset of the event after dosing.
No adverse event (AE) was reported in more than one patient
per treatment group, and none were considered treatment-re-
lated. No conjunctivitis or other superficial eye disorder, herpes
viral infection or injection-site reactions were reported.
The number of TEAEs was higher in the younger cohorts (11
in each dose group; Table 3). Most were mild to moderate. Two
patients in the 6 mg/kg dose group had an AE related to study
drug (diarrhea and injection-site erythema), neither of which
was severe or serious. One patient in the 3 mg/kg dose group
had a serious TEAE, an anaphylactic reaction immediately after
eating crab and >2 weeks after dosing; therefore, the TEAE was
deemed unrelated to dupilumab. Besides nasopharyngitis, no AE
was reported in more than one patient in either treatment group
(Table 3). No conjunctivitis or other superficial eye disorders or
herpes viral infections were reported. No deaths occurred during
the study.
Biomarker analysis
In both older and younger patients, dupilumab at both doses
markedly suppressed serum TARC and total IgE (Table 4).
Blood eosinophil count at week 4 marginally increased in older
patients but decreased in younger patients in the 3 mg/kg
groups; it remained unchanged after 6 mg/kg dupilumab in the
older and younger cohorts (Table 4).
Concomitant TCS use for AD
The majority of patients in both the younger (80% and 60%
with 3 and 6 mg/kg, respectively) and older cohort (90% and
80% with 3 and 6 mg/kg, respectively) used concomitant TCS
for AD during the study (Table S2, Supporting Information).
Most of the concomitant TCS used was of moderate potency
(group II); none of the patients used very potent (group IV)
TCS during the study (Table S2, Supporting Information).
Discussion
Both dose groups in both age cohorts experienced improvement
in AD signs and symptoms as measured by EASI, total
SCORAD, SCORAD VAS for sleep and itch, and caregiver-re-
ported Peak Pruritus NRS scores at week 3. However, there was
a trend towards slightly better responses in the older vs. younger
age cohort, particularly when comparing the 6 mg/kg dose
groups. At week 4, not all benefits were sustained in either age
cohort, and loss of efficacy was more pronounced in the lower
dose group. These findings support the need for repeated
administration.
Dupilumab exhibits non-linear, target-mediated PK as previ-
ously characterized in adult42,43 and adolescent33 patients with
moderate-to-severe AD and supported by the greater than dose-
proportional increases in AUC observed in the current study.
Slightly lower exposures were observed in the younger patients
than in the older patients at the same mg/kg dose level in this
study. It has been described previously for monoclonal antibod-
































Dupilumab 3 mg/kg  ≥2 to <6 years (n = 9)
Dupilumab 6 mg/kg  ≥2 to <6 years (n = 10)
Dupilumab 3 mg/kg  ≥6 months to <2 years (n = 10)
Dupilumab 6 mg/kg  ≥6 months to <2 years (n = 10)
Figure 2 Pharmacokinetics of single-dose dupilumab over time in
the two age cohorts (≥6 months to <2 years and ≥2 to <6 years):
mean (SD) concentrations by dose group and nominal time on log-
linear scale. Samples below the LLoQ were set to LLoQ/2. In the
older cohort, dupilumab was undetectable at all time points in one
patient who received the 3 mg/kg dose; this patient was excluded
from all summary plots and descriptive statistics. LLoQ, lower limit
of quantitation; n, number of patients; SD, standard deviation.
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Table 2 Efficacy outcomes









Baseline Week 3 Week 4 Baseline Week 3 Week 4 Baseline Week 3 Week 4 Baseline Week 3 Week 4
EASI score, mean (SD) 35.2 (9.21) 20.9 (17.31) 26.2 (18.44) 40.2 (11.81) 20.1 (12.25) 20.9 (12.87) 34.4 (14.25) 22.4 (19.70) 27.0 (15.75) 36.1 (12.94) 22.4 (12.23) 21.2 (17.44)
EASI score % change from
baseline, mean (SD)
N/A 44.6 (36.77) 26.6 (47.37) N/A 49.7 (29.05) 48.7 (28.89) N/A 42.7 (33.13) 22.4 (42.52) N/A 38.8 (24.98) 43.2 (35.55)
95% CI of mean N/A 70.9, 18.3 60.5, 7.3 N/A 70.5, 29.0 69.3, 28.0 N/A 66.4, 19.0 52.9, 8.0 N/A 56.7, 20.9 68.6, 17.8
Total SCORAD score, mean
(SD)
73.5 (10.20) 50.1 (26.88) 60.1 (22.02) 75.1 (8.08) 49.5 (19.26) 51.6 (15.79) 69.8 (13.10) 48.7 (23.21) 55.2 (21.34) 75.9 (11.74) 56.2 (13.84) 54.9 (24.50)
Total SCORAD % change
from baseline, mean (SD)
N/A 33.0 (32.09) 18.6 (26.18) N/A 34.7 (23.18) 31.9 (17.45) N/A 32.9 (23.76) 22.4 (26.44) N/A 25.2 (17.18) 28.1 (27.84)
95% CI of mean 55.9, 10.0 37.4, 0.1 51.3, 18.1 44.4, 19.4 49.9, 15.9 41.3, 3.5 37.5, 12.9 48.1, 8.2
SCORAD VAS sleep score,
mean (SD)
6.3 (2.54) 5.5 (3.87) 5.1 (3.76) 6.3 (2.82) 3.2 (2.39) 4.0 (3.01) 6.0 (2.83) 4.2 (2.96) 4.3 (3.00) 7.8 (1.90) 4.8 (2.52) 6.0 (3.49)
SCORAD VAS sleep score %
change from baseline, mean
(SD)
N/A 2.8 (92.32)† 11.8 (136.08)† N/A 44.1 (48.42) 37.9 (35.08) N/A 32.8 (39.83) 25.2 (53.14) N/A 34.5 (39.75) 24.3 (46.68)
95% CI of mean 68.9, 63.2 85.5, 109.2 78.8, 9.5 63.0, 12.8 61.3, 4.3 63.2, 12.9 62.9, 6.1 57.7, 9.1
SCORAD VAS itch score,
mean (SD)
8.4 (1.18) 6.0 (3.29) 7.2 (2.81) 7.6 (1.78) 4.2 (1.92) 5.2 (1.84) 7.5 (2.40) 5.1 (2.31) 5.9 (2.57) 8.2 (1.42) 6.3 (2.77) 6.4 (3.20)
SCORAD VAS itch score %
change from baseline, mean
(SD)
N/A 30.0 (34.68) 14.1 (30.22) N/A 44.5 (26.04) 27.1 (35.17) N/A 27.0 (33.73) 11.7 (48.44) N/A 19.2 (43.49) 24.7 (31.09)
95% CI of mean 54.8, 5.2 35.7, 7.5 63.1, 25.8 52.2, 1.9 51.1, 2.9 46.4, 22.9 50.4, 11.9 47.0, 2.5
Patients with IGA 0 or 1, n/N
(%)
N/A 0 1 (10) N/A 0 0 N/A 0 1 (10.0) N/A 0 1 (10.0)
95% CI of mean 0, 30.85 0.25, 44.50 0, 30.85 0, 30.85 0, 30.85 0.25, 44.50 0, 30.85 0.25, 44.50
Patients with EASI-50, n/N
(%)
N/A 5 (50.0) 3 (30.0) N/A 5 (50.0) 4 (40.0) N/A 5 (50.0) 2 (20.0) N/A 4 (40.0) 4 (40.0)
95% CI of mean 18.71, 81.29 6.67, 65.25 18.71, 81.29 12.16, 73.76 18.71, 81.29 2.52, 55.61 12.16, 73.76 12.16, 73.76
Patients with EASI-75, n/N
(%)
N/A 3 (30.0) 2 (20.0) N/A 2 (20.0) 3 (30.0) N/A 2 (20.0) 2 (20.0) N/A 0 3 (30.0)
95% CI of mean 6.67, 65.25 2.52, 55.61 2.52, 55.61 6.67, 65.25 2.52, 55.61 2.52, 55.61 0, 30.85 6.67, 65.25
Caregiver-reported Peak
Pruritus NRS score, mean
(SD)
8.4 (1.2) 6.7 (2.8) 7.1 (3.1) 8.1 (1.4) 4.5 (1.6) 6.1 (2.3) 7.6 (2.5) 5.8 (2.2) 6.5 (2.1) 8.5 (0.7) 7.0 (2.4) 6.3 (3.2)
Caregiver-reported Peak
Pruritus NRS score, %
change from baseline, mean
(SD)
N/A 22.9 (29.9) 16.7 (32.5) N/A 44.7 (17.5) 22.0 (34.5) N/A 11.1 (57.5)† 4.1 (84.2)† N/A 18.2 (26.4) 26.7 (35.5)
% BSA affected, mean (SD) 58.1 (11.09) 38.1 (20.74) 42.2 (20.95) 67.5 (16.05) 39.5 (17.46) 37.2 (22.03) 55.3 (25.66) 46.2 (30.41) 50.1 (29.54) 57.9 (21.37) 35.0 (18.79) 33.0 (24.70)
% BSA affected, % change
from baseline, mean (SD)
N/A 34.5 (33.66) 23.8 (41.82) N/A 40.8 (25.72) 43.6 (29.56) N/A 22.1 (31.57) 12.3 (38.38) N/A 40.3 (21.21) 44.8 (31.75)
95% CI of mean 58.6, 10.4 53.8, 6.1 59.2, 22.4 64.7, 22.4 44.6, 0.5 39.8, 15.1 55.4, 25.1 67.5, 22.0`
BSA, body surface area; CI, confidence interval; EASI, Eczema Area and Severity Index; EASI-50/-75, ≥50%/≥75% improvement from baseline in EASI; IGA, Investigator’s Global Assessment; N/A, not
applicable; NRS, Numerical Rating Scale; SCORAD, SCORing Atopic Dermatitis; SD, standard deviation; VAS, visual analog scale.
†The apparent lack of efficacy in this age and dose subgroup is due to an outlier patient with a SCORAD VAS sleep loss score of 1.8, 5.6, 8.4 at baseline, week 3 and week 4, respectively, with a corre-
sponding percentage change from baseline of 211.1% and 366.7% for weeks 3 and 4, respectively. ‡The apparent lack of efficacy in this age and dose subgroup is due to an outlier patient with a care-














































































































































































clearance does not scale linearly with body weight. This mani-
fests as faster clearance on a per kilogram of total body weight in
smaller individuals. Accordingly, using the same mg/kg dose
regimen across a wide weight range in a pediatric population
overcorrects dose for the impact of body weight and results in





Figure 3 Efficacy outcomes in the two age cohorts (≥6 months to <2 years and ≥2 to <6 years): (a) mean percentage change from base-
line to week 4 in EASI; (b) mean percentage change from baseline to week 4 in SCORAD score; (c) proportions of patients with EASI-50;
(d) proportions of patients with EASI-75 from baseline to week 4; (e) mean percentage change from baseline to week 4 in caregiver-re-
ported Peak Pruritus NRS. EASI, Eczema Area and Severity Index; EASI-50/-75, ≥50%/≥75% improvement from baseline in EASI; NRS,
numerical rating scale; SCORAD, SCORing Atopic Dermatitis; SD, standard deviation.
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Maintaining sufficient concentrations of antagonistic antibod-
ies such as dupilumab is important for blocking target pathways
throughout the intended duration of treatment. When adminis-
tered under similar multiple dosing scenarios, the faster elimina-
tion on a per kilogram of total body weight basis may require
larger body weight-normalized doses in younger populations to
maintain similar trough concentrations. This is supported by the
fact that a single dupilumab 300 mg dose in adults, equivalent
to ≤5 mg/kg in a ≥60 kg adult, leads to a similar exposure to the
6 mg/kg dose used in this study. Other mechanisms such as
higher levels of interleukin IL-13 gene expression in non-lesional
AD skin in children than adults23 may also contribute to more
rapid drug removal by receptor-mediated pathways in young
children. The use of an appropriate weight-tiered dosing regi-
men of dupilumab, similar to that used in other pediatric popu-
lations, is an acceptable approach to normalizing exposure
across a range of patient demographics.31
Overall, single-dose dupilumab treatment suppressed serum
type 2 inflammatory biomarkers TARC and total IgE, consistent
with findings in adolescents31 and adults,46 suggesting a shared
Table 3 Safety assessment at week 4










Total number of TEAEs 5 3 11 11
Total number of serious TEAEs 1 0 1 0
Total number of TEAEs related to treatment 0 0 0 2
Patients with TEAEs, n (%)
≥1 TEAE 3 (30.0) 2 (20.0) 7 (70.0) 7 (70.0)
≥1 serious TEAE 1 (10.0) 0 1 (10.0) 0
≥1 severe TEAE 0 0 1 (10.0) 0
Any infection (SOC) 2 (20.0) 1 (10.0) 3 (30.0) 4 (40.0)
Skin infection† 1 (10.0) 0 2 (20.0) 1 (10.0)
Non-herpetic skin infection† 1 (10.0) 0 2 (20.0) 1 (10.0)
Impetigo (PT) 1 (10.0) 0 1 (10.0) 1 (10.0)
Folliculitis (PT) 0 0 1 (10.0) 0
Herpes viral infections (HLT) 0 0 0 0
Injection-site reactions (HLT) 0 0 0 1 (10.0)
Injection-site erythema (PT) 0 0 0 1 (10.0)
TEAEs (PT), n (%)‡
Nasopharyngitis 1 (10.0) 1 (10.0) 1 (10.0) 2 (20.0)
Diarrhea 0 0 1 (10.0) 1 (10.0)
Upper respiratory tract infection 0 0 1 (10.0) 1 (10.0)
Urticaria 0 0 1 (10.0) 1 (10.0)
Dermatitis atopic 1 (10.0) 0 0 1 (10.0)
Cough 0 1 (10.0) 0 1 (10.0)
Pyrexia 1 (10.0) 0 1 (10.0) 0
Anaphylactic reaction 1 (10.0) 0 1 (10.0) 0
Constipation 0 0 1 (10.0) 0
Folliculitis 0 0 1 (10.0) 0
Joint swelling 0 0 1 (10.0) 0
Lacrimation increased 0 0 0 1 (10.0)
Skin abrasion 0 1 (10.0) 0 0
Teething 0 0 1 (10.0) 0
Thrombocytosis 0 0 0 1 (10.0)
Conjunctivitis 0 0 0 0
Herpes simplex 0 0 0 0
Adverse events reported according to MedDRA PTs unless otherwise specified.
HLT, MedDRA High Level Term; MedDRA, Medical Dictionary for Regulatory Activities; PT, MedDRA Preferred Term; SOC, MedDRA System Organ Class;
TEAE, treatment-emergent adverse event.
†Adjudicated. ‡Includes all MedDRA PTs reported in ≥10% of patients in any treatment group of the study.
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Table 4 Blood serum biomarkers









Baseline Week 4 Baseline Week 4 Baseline Week 4 Baseline Week 4























N/A 26.4 (53.5, 7.1) N/A 66.4 (90.4, 59.0) N/A 21.1 (56.4, 464.4) N/A 57.6 (77.2, 10.5)
n 9 9 10 10 10 9 10 8
Total IgE concentration,

















Total IgE, median %
change from baseline
(Q1, Q3), IU/mL
N/A 20.38 (28.24,6.01) N/A 32.85 (44.96,11.52) N/A 23.25 (27.04,13.79) N/A 37.27 (53.58,5.43)
n 10 10 10 9 9 9 10 9
Blood eosinophil count,
median (Q1, Q3), 9109/L





N/A 0.10 (0.40, 0.80) N/A 0.00 (0.20, 0.10) N/A 0.10 (0.70, 0.20) N/A 0.00 (0.50, 0.20)

































































































































































































underlying mechanism of inflammation involving interleukin-4
and interleukin-13 as mediators. Indeed, even pediatric patients
aged <2 years with recent-onset AD have shown a strong Th2-
skewed immune response.23,24 There was no clear effect of sin-
gle-dose dupilumab on blood eosinophil count.
The safety profile of dupilumab in children aged ≥6 months
to <6 years was comparable to that seen in adults, adolescents
and children >6 years.28–32 There were no dupilumab-related
events of serious infection or systemic hypersensitivity.
The greater number of TEAEs in the younger cohort appeared
not to be driven by any particular event, and the majority of
events were deemed unrelated to dupilumab. The acceptable
safety profile helped to address theoretical concerns about the
use of immunomodulating treatment in young children, and
supports the use of a targeted immunomodulatory treatment
instead of a broad systemic immunosuppressant. Supporting
safety data after multiple-dose treatment would differentiate use
of a targeted immunomodulator such as dupilumab from broad
immunosuppressants currently used off-label in young children.
Strengths and limitations
This is the first study of a targeted biologic agent in children
with severe AD. Because this pilot study was not powered for
efficacy analyses, we do not report inferential statistics. As the
majority of patients used concomitant TCS during the study (as
allowed), the efficacy results may have been confounded. Never-
theless, the promising safety and efficacy results from this small
single-dose exposure, the first to treat children as young as
6 months old with a biologic agent for AD, support a larger,
multiple-dose, phase 3 study of dupilumab in this patient popu-
lation.
Conclusions
A single subcutaneous dose of dupilumab in children ≥6 months
to <6 years with severe AD yielded substantial clinical benefit in
reducing signs and symptoms of AD, with no clear dose-re-
sponse observed at week 3. However, at week 4, improvements
in most efficacy responses started to reverse, particularly in the
lower dose group. There was a trend towards slightly higher
exposure and efficacy in the older (≥2 to <6 years) vs. younger
age group (≥6 months to <2 years). Dupilumab was generally
well tolerated in this pediatric population, and its safety profile
was similar to that in adults, adolescents and children >6 years.
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